

REAL-WORLD EXPERIENCE WITH PCSK9 INHIBITORS PROTOCOL FOR HYPERCHOLESTEROLEMIA

M.I. SÁEZ RODRÍGUEZ¹, J.J. ARENAS VILAFRANCA¹, B. MONTERO SALGADO¹, P.A. CHINCHURRETA CAPOTE², B. TORTAJADA GOITIA¹.

¹COSTA DEL SOL HOSPITAL, PHARMACY, MARBELLA, SPAIN.
²COSTA DEL SOL HOSPITAL, CARDIOLOGY, MARBELLA, SPAIN.

BACKGROUND AND OBJECTIVES

CSK9 inhibitors (PCSK9i) are drugs that reduce low density lipoprotein (LDL) levels. Due to their high cost and restrictive indications, a Drug Use Evaluation (DUE) was performed.

AIM AND OBJECTIVES

Evaluate a protocol for PCSK9i use and patients' follow-up developed in our center.


MATERIAL AND METHODS

All patients with PCSK9i were included in the study.

Variables:

- Sex, age
- Last appointment with the doctor
- LDL-levels before treatment (LDL-1)
- LDL-levels after one month (LDL-2)
- In patients with more than one year treatment, date and results of the last LDL analytic (LDL-3).

A **descriptive analysis** was performed using measures of central tendency, dispersion and position for quantitative variables, and frequency distribution for qualitative variables.



RESULTS

161 patients were included

♂ 67,7% male ♀ 32,3% female

Medium age was 60±8,7 years

⌚ Follow up ranged from 2 months to 5 years

Treatment regimens

Evolocumab 140 mg / 2 weeks: 30 (18,6%)
Alirocumab 75 mg / 2 weeks: 96 (59,6%)
Alirocumab 150 mg / 2 weeks: 35 (21,7%).

17 patients (10,55%) didn't have an analytic in the last year, and 10 patients (6,21%) hadn't had an appointment with their doctor in more than a year.

	Minimum (mg/dl)	Maximum (mg/dl)	Medium (mg/dl)
LDL-1 (n = 161)	66	344	132,5 ± 47,3
LDL-2 (n = 158)	8	188	60,49 ± 34,04
LDL-3 (n = 122)	7	160	61,59 ± 33,96

Medium **LDL-levels improvement** after one month was **71,7±41,2 mg/dl**.

38 patients (23,6%) had **LDL-levels over the objective**. According to guidelines and protocol, these patients were referred to the physician for revision

CONCLUSION AND RELEVANCE

Although some patients don't reach the desired outcome and/or their monitoring may be improved, our data shows that **PCSK9i cause a great reduction of LDL levels that is maintained in time**.

4CPS-119

Contact data: Ml Sáez.
maissaro@hcs.es